- Home
- BCLI vs SNGX Comparison
BCLI vs SNGX Comparison
Compare BCLI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- SNGX
- Stock Information
- Founded
- BCLI 2000
- SNGX 1987
- Country
- BCLI United States
- SNGX United States
- Employees
- BCLI N/A
- SNGX N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- SNGX Health Care
- Exchange
- BCLI Nasdaq
- SNGX Nasdaq
- Market Cap
- BCLI 6.4M
- SNGX 6.5M
- IPO Year
- BCLI N/A
- SNGX 1987
- Fundamental
- Price
- BCLI $0.92
- SNGX $2.16
- Analyst Decision
- BCLI Strong Buy
- SNGX
- Analyst Count
- BCLI 1
- SNGX 0
- Target Price
- BCLI $30.00
- SNGX N/A
- AVG Volume (30 Days)
- BCLI 366.6K
- SNGX 199.2K
- Earning Date
- BCLI 05-13-2025
- SNGX 05-09-2025
- Dividend Yield
- BCLI N/A
- SNGX N/A
- EPS Growth
- BCLI N/A
- SNGX N/A
- EPS
- BCLI N/A
- SNGX N/A
- Revenue
- BCLI N/A
- SNGX $119,371.00
- Revenue This Year
- BCLI N/A
- SNGX N/A
- Revenue Next Year
- BCLI N/A
- SNGX N/A
- P/E Ratio
- BCLI N/A
- SNGX N/A
- Revenue Growth
- BCLI N/A
- SNGX N/A
- 52 Week Low
- BCLI $0.72
- SNGX $1.68
- 52 Week High
- BCLI $10.05
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- BCLI 35.85
- SNGX 51.88
- Support Level
- BCLI $1.12
- SNGX $1.97
- Resistance Level
- BCLI $0.82
- SNGX $2.23
- Average True Range (ATR)
- BCLI 0.12
- SNGX 0.17
- MACD
- BCLI 0.01
- SNGX 0.02
- Stochastic Oscillator
- BCLI 36.36
- SNGX 86.36
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).